Abstract
This work reports the development and validation of an ultra-high-performance liquid chromatography method to separate 11 different cardiovascular drugs: acenocoumarol, amiloride, bisoprolol, fluvastatin, furosemide, glibenclamide, hydrochlorothiazide, rosiglitazone (internal standard), valsartan, verapamil and warfarin. Detection of the analytes was carried out by means of photodiode array and fluorescence detection. Initially, the most significant variables in liquid chromatography (pH of the mobile phase, nature of the organic modifier and stationary phase type) were studied simultaneously in a systematic way. Taking into account the resolution obtained for the different chromatographic separations, pH 4.5, methanol and C18 were chosen as mobile phase pH, organic modifier and stationary phase, respectively. The method was validated and applied to the analysis of real human plasma samples using a solid phase extraction sample treatment, and the robustness of the chromatographic separation was studied by experimental design. The reported method allows the separation of all the analytes and the IS in less than 6 min, and, furthermore, it simplifies the analysis of drugs used in combined cardiovascular therapy by applying a fast and simple methodology.
Similar content being viewed by others
References
World Health Organization (2015) Fact sheet: noncommunicable diseases. http://www.who.int/mediacentre/factsheets/fs355/en/. Accessed May 2015
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics C, Stroke Statistics S (2016) Circulation 133:e38–e360
Lafeber M, Spiering W, Visseren FL, Grobbee DE (2016) Curr Hypertens Rep 18:40
Barrios V, Escobar C (2016) Future Cardiol 12:181–196
Baranowska I, Wilczek A, Baranowski J (2010) Analy Sci: Int J Jpn Soc Anal Chem 26:755–759
Dinç E, Ertekin C, Rouhani G (2015) J Liq Chromatogr Relat Technol 38:970–976
Dobricic V, Vulovic-Tadic M, Jancinc-Stojanovic B, Vladimirov S, Cudina O (2016) Chromatographia 79:571–579
Joshi SJ, Karbhari PA, Bhoir SI, Bindu KS, Das C (2010) J Pharm Biomed Anal 52:362–371
Gonzalez O, Ferreiros N, Blanco ME, Alonso RM (2015) Bioanalysis 7:2399–2417
Baranowska I, Magiera S, Baranowski J (2013) J Chromatogr B 927:54–79
Soltani S, Ramezani AM, Soltani N, Jouyban A (2012) Bioanalysis 4:2805–2821
Lasky T, Greenspan J, Ernst FR, Gonzalez L (2011) Clin Ther 33:2082–2088
Dias E, Hachey B, McNaughton C, Nian H, Yu C, Straka B, Brown NJ, Caprioli RM (2013) J Chromatogr B 937:44–53
Magiera S, Baranowska I, Kusa J (2012) Talanta 89:47–56
Andre C, Jorge F, Castanheira I, Matos A (2013) J Chemom 27:91–98
Zhou Y, Song J-Z, Choi FF-K, Wu H-F, Qiao C-F, Ding L-S, Gesang S-L, Xu H-X (2009) J Chromatogr A 1216:7013–7023
Baranowska I, Magiera S, Baranowski J (2011) J Chromatogr B 879:615–626
Snyder L, Kirkland J, Dolan J (2009) Introduction to modern liquid chromatography. Wiley, New Jersey
European Medicines Agency (2011) EMEA/CHMP/EWP/192217/2009, guideline on bioanalytical method validation
US Department of Health and Human Services, Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation
Esbensen K (2001) Multivariate data analysis in practice. CAMO, Oslo
Dejaegher B, Vander Heyden Y (2007) J Chromatogr A 1158:138–157
Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BGM, Massart DL (2001) J Pharm Biomed Anal 24:723–753
Vander Heyden Y, Questier F, Massart DL (1998) J Pharm Biomed Anal 17:153–168
W-d Zhang, W-j Yang, Wang X-j GuY, Wang R (2011) J Chromatogr B 879:3735–3741
Tan KL, Ankathil R, Gan SH (2011) J Chromatogr B 879:3583–3591
Acknowledgements
Authors thank Ministry of Economy and Competitiveness (Project CTQ2013- 46179R), University of Basque Country (GIU 16/04 and UFI 11/23) for financial support and the pharmaceutical companies for the kind supply of studied drugs. M. E. Blanco also thanks the University of the Basque Country (UPV/EHU) for her postdoctoral grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
González Mendia, O., Blanco, M.E., Rico, E. et al. Efficient Method Development and Validation for the Determination of Cardiovascular Drugs in Human Plasma by SPE–UHPLC–PDA–FLD. Chromatographia 80, 605–615 (2017). https://doi.org/10.1007/s10337-017-3274-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-017-3274-6